lyca

Lycia Therapeutics Goes Public: The Protein-Degradation Story to Watch

Lycia Therapeutics (NASDAQ: LYCA) is expected to list on 2026-10-23 at a price range of $16.00 to $18.00 per share. The company is offering 14,700,000 shares in an IPO built around its LYTAC and cataLYTAC protein-degradation platform. The bull case is a differentiated shot at hard-to-drug extracellular targets; the bear case is that it is still pre-commercial with no clinical-trial readouts yet.